Pharmaceutical company Boehringer Ingelheim has announced plans to lay off a number of salespeople due to lower-than-expected sales of its biosimilar version of the popular drug Humira. The decision comes as the company faces challenges in gaining market share for its biosimilar product.
Humira, a widely used medication for treating autoimmune diseases, has been a major revenue driver for many pharmaceutical companies. Boehringer had high hopes for its biosimilar version, which was expected to offer a more affordable alternative to Humira. However, sales of the biosimilar have not met expectations, leading to the need for cost-cutting measures.
